29 April 2024
Aminex plc
("Aminex" or "the Company")
Funding Facility agreed with Eclipse Investments
Aminex, the oil and gas exploration and development company focused on Tanzania, is pleased to announce that it has agreed a funding facility with its largest shareholder, Eclipse Investments LLC (Eclipse). The main terms of the facility are:
· The facility is for $3 million, available for up to 24 months
· The first $1.5 million tranche is guaranteed, with the remaining tranche available at Eclipse's discretion
· Any advances drawn down will be set-off against the Company's $35 million carry in respect of the Ntorya development from ARA Petroleum Tanzania (Carry), at Eclipse's discretion
· Interest will accrue on any advances at the rate of the Standard Overnight Financing Rate + 8%
· If not already set-off against the Carry, Eclipse can demand repayment, but not before 31 December 2026
· There is no security granted against the facility and no arrangement fees payable by the Aminex group.
Charles Santos, Executive Chairman of Aminex commented:
"We are very grateful to Eclipse for their continuing support and for agreeing to put this funding facility in place, should the Company need it. As announced in 2022, the Company has sufficient funds until the end of 2024, when revenues from the Ntorya gas discovery had originally been expected. However, final preparations are ongoing to enable work on the Ntorya development to start and this leads us to now estimate first revenues in mid-2025. We therefore believe it is prudent to arrange this funding now."
For further information:
|
|
Aminex PLC |
+44 203 355 9909 |
Charles Santos, Executive Chairman |
|
|
|
Knights Media & Public Relations |
+44 203 653 0200 |
Jason Knights, Sabina Zawadzki |
|
|
|
Davy |
+353 1 679 6363 |
Brian Garrahy
|
|
Shard Capital |
+44 20 7186 9952 |
Damon Heath |
|
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.